Prothena (PRTA) Rallies Along With Biogen (BIIB)
b"Prothena (PRTA) stock price today was up over 87%. Prothena is a late-stage clinical company engaged in the protein dysregulation. Their pipeline includes Parkinson's disease and Alzheimer's therapies. The PRTA stock was upgraded following positive data from Biogen (BIIB). George Tsilis weighs in on the BOFA analyst note that stated Prothena trial result is a big milestone in the treatment of Alzheimer's disease."